Yahoo Web Search

  1. Two Cell Signaling Technology antibody clones, ALK (D5F3®) and ROS1 (D4D6®), were featured in an article authored by the Tumor Biomarker Experts of the Chinese Society of Clinical Oncology ...

  2. According to the lawsuit, defendants during the Class Period violated the federal securities laws by: (1) withholding relevant trial data showing that Prothena’s NEOD001, an antibody ...

  3. Sarepta Therapeutics Inc. (SRPT) touched a new high of $176.50 on June 19, following positive preliminary results from its phase 1/2a gene therapy micro-dystrophin trial for the treatment of ...

  4. The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The...

  5. SAN DIEGO, June 23, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy ...

  6. Technavio has announced their latest pipeline analysis report on the malignant glioma market. The report includes a detailed analysis of the pipeline molecules under investigation within the ...

  7. Jun 20, 2018 (Heraldkeeper via COMTEX) -- Antibody Drug Conjugate Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and strategies Cover in this ...

  8. Global Antibody Drug Conjugates Market Expected to Reach $3,198 Million by 2023 PR Newswire PORTLAND, Oregon and PUNE, India, June 21, 2018 PORTLAND, Oregon and PUNE, India,...

  9. Final results from the phase 3 CLL11 trial confirm the superiority of the newer anti-CD20 monoclonal antibody drug obinutuzumab (Gazyva) compared to the older agent rituximab (Rituxan ...

  10. The companies will jointly develop the product on a worldwide basis, focusing on indications in the area of hematologic B-cell malignancies. TG Therapeutics will make up-front and milestones ...

  1. 12345259 results